Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with
potent inhibitory activity against the ErbB and VEGF receptor family of tyrosine kinases. It
has an IC50 of less than 100 nM against p-EGFR, p-ErbB2, and p-KDR (VEGFR2). This study will
assess the safety, pharmacokinetic/pharmacodynamic (PK/PD) profiles and clinical activity of
AEE788 in a recurrent GBM population.